文献速递腹部CT

对比增强CT测量肝脏细胞外容积分数评估慢性丙型肝炎患者直接抗病毒治疗前后肝纤维化:与血清学标志物比较

Evaluation of liver fibrosis using hepatic extracellular volume fraction by contrast-enhanced computed tomography before and after direct-acting antiviral therapy in patients with chronic hepatitis C infection: comparison with serological liver fibrosis markers.
PubMed 文献 · Br J Radiol · 2021-09-29

本研究评估41例接受直接抗病毒治疗并获得持续病毒学应答的丙型肝炎患者及10例对照,利用对比增强CT测量肝脏细胞外容积分数,并与FIB-4指数和APRI比较。结果显示治疗后细胞外容积分数缓慢下降,而血清学标志物立即下降,提示细胞外容积分数可能反映肝纤维化改善,而血清学标志物可能反映炎症改善。

要点

  • 直接抗病毒治疗后细胞外容积分数缓慢下降,可能反映肝纤维化改善。
  • 血清学纤维化标志物FIB-4和APRI在治疗后立即下降,可能反映炎症改善。
  • 细胞外容积分数有潜力作为评估治疗后肝纤维化的无创生物标志物。

诊断标准与关键数值

  • 在持续病毒学应答组,细胞外容积分数在T1与T4比较(p=0.046)及T1与T5比较(p=0.022)差异有统计学意义。
  • 在持续病毒学应答组,FIB-4指数和APRI在T1与所有其他时间点比较差异均有统计学意义(p=0.017至p<0.001和p=0.001至p<0.001)。
  • 在对照组,FIB-4指数仅在T2与T4比较差异有统计学意义(p=0.046),APRI仅在T2与T4比较差异有统计学意义(p=0.028)。

局限性

  • 对照组样本量较小(10例),可能影响统计效力。
  • 研究未报告细胞外容积分数的具体测量方法或阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate time-dependent changes in hepatic extracellular volume (ECV) fraction using contrast-enhanced CT (CECT) and serological liver fibrosis markers, the fibrosis-4 (FIB-4) index and aspartate aminotransferase to platelet ratio index (APRI), before and after direct-acting antiviral therapy (DAA) for hepatitis C virus (HCV) infection.

METHODS: 41 HCV-infected patients who achieved sustained virological response (SVR) after DAA (SVR group) and 10 control patients (untreated or unresponsive to treatment) who underwent CECT and serum biochemical tests before or after the first examination/DAA (T1) and at intervals thereafter (T2:<6 months after T1, T3: at 6-12 months, T4: at 12-24 months, and T5:>24 months) were evaluated.

RESULTS: In the control group, ECV fractions remained relatively unchanged through the study, and significant differences in FIB-4 index comparisons and APRI comparisons were only seen between the T2 and T4 values (p = 0.046 and p = 0.028, respectively). In the SVR group, ECV fractions were significantly different between T1 and T4 and T1 and T5 (p = 0.046 and 0.022, respectively), and both FIB-4 index and APRI were significantly different between T1 and all other time points (p = 0.017 to p < 0.001 and p = 0.001 to p < 0.001, respectively).

CONCLUSION: After DAA, ECV fraction decreased slowly, suggesting an improvement in hepatic fibrosis, while serological liver fibrosis markers decreased immediately, probably due to improvement in hepatic inflammation.

ADVANCES IN KNOWLEDGE: ECV fraction has the potential to be a non-invasive biomarker for the assessment of liver fibrosis after direct-acting antiviral therapy.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Kanki A, Maeba K, Sotozono H, et al. Evaluation of liver fibrosis using hepatic extracellular volume fraction by contrast-enhanced computed tomography before and after direct-acting antiviral therapy in patients with chronic hepatitis C infection: comparison with serological liver fibrosis markers. Br J Radiol. 2021. PMID: 34586878. doi:10.1259/bjr.20210045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。